Major Challenges in Rheumatology: Will We Ever Treat Smarter, Instead of Just Harder?

Frontiers in Medicine

article

Vasco C. Romão¹  João Eurico Fonseca¹ 

[1] Department of Rheumatology, Centro Hospitalar Universitário Lisboa Norte, Hospital de Santa Maria, Lisbon Academic Medical Centre;Rheumatology Research Unit, Instituto de Medicina Molecular, Universidade de Lisboa

关键词: rheumatology;    personalized medicine;    stratification;    rheumatoid arthritis;    biomarkers;   

DOI  :  10.3389/fmed.2019.00144

学科分类：社会科学、人文和艺术（综合）

来源: Frontiers

【 摘 要 】

The field of rheumatology has witnessed astonishing progress in the understanding and management of rheumatic diseases since the second half of the twentieth century. The discovery and introduction of glucocorticoids and conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) into the therapeutic armamentarium of rheumatologists enabled, for the first time, to effectively change the natural course of disease and improve most clinical outcomes (1). The new millennium pushed the revolution further at an exponential level with the advent of sophisticated, biologically-engineered drugs—the so-called biologicals or bDMARDs—that targeted specific molecules in key pathogenic pathways and dramatically modified the prognosis of most patients with immune-mediated rheumatic diseases (2).

【 授权许可】

CC BY